You can seek FDA approval to launch a generic drug before the expiration of ABILIFY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY:-

You can seek FDA approval to launch a generic drug before the expiration of ABRAXANE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABRAXANE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABRAXANE:-

You can seek FDA approval to launch a generic drug before the expiration of ACETADOTE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACETADOTE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACETADOTE:-

You can seek FDA approval to launch a generic drug before the expiration of ACTOPLUS MET XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACTOPLUS MET XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACTOPLUS MET XR:-

You can seek FDA approval to launch a generic drug before the expiration of ADEMPAS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADEMPAS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADEMPAS:-

You can seek FDA approval to launch a generic drug before the expiration of ADZENYS XR-ODT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ADZENYS XR-ODT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ADZENYS XR-ODT:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of AFINITOR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AFINITOR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AFINITOR:-

You can seek FDA approval to launch a generic drug before the expiration of AMPYRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AMPYRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AMPYRA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of APLENZIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the APLENZIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on APLENZIN:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of APTIOM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the APTIOM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on APTIOM:-

You can seek FDA approval to launch a generic drug before the expiration of ARICEPT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ARICEPT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ARICEPT:-

You can seek FDA approval to launch a generic drug before the expiration of ATELVIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ATELVIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ATELVIA:-

You can seek FDA approval to launch a generic drug before the expiration of ATRIPLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ATRIPLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ATRIPLA:-

You can seek FDA approval to launch a generic drug before the expiration of AUBAGIO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AUBAGIO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AUBAGIO:-

You can seek FDA approval to launch a generic drug before the expiration of AXIRON's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AXIRON's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AXIRON:-

You can seek FDA approval to launch a generic drug before the expiration of BELEODAQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELEODAQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELEODAQ:-

You can seek FDA approval to launch a generic drug before the expiration of BELRAPZO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELRAPZO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELRAPZO:-

You can seek FDA approval to launch a generic drug before the expiration of BENDEKA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BENDEKA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BENDEKA:-

You can seek FDA approval to launch a generic drug before the expiration of BOSULIF's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BOSULIF's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BOSULIF:-

You can seek FDA approval to launch a generic drug before the expiration of BRIDION's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BRIDION's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BRIDION:-

You can seek FDA approval to launch a generic drug before the expiration of BRISDELLE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BRISDELLE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BRISDELLE:-

You can seek FDA approval to launch a generic drug before the expiration of BRIVIACT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BRIVIACT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BRIVIACT:-

You can seek FDA approval to launch a generic drug before the expiration of BYVALSON's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BYVALSON's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BYVALSON:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of CABOMETYX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CABOMETYX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CABOMETYX:-

You can seek FDA approval to launch a generic drug before the expiration of CALQUENCE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CALQUENCE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CALQUENCE:-

You can seek FDA approval to launch a generic drug before the expiration of CAMBIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CAMBIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CAMBIA:-

You can seek FDA approval to launch a generic drug before the expiration of CERDELGA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CERDELGA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CERDELGA:-

You can seek FDA approval to launch a generic drug before the expiration of CLINDESSE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CLINDESSE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CLINDESSE:-

You can seek FDA approval to launch a generic drug before the expiration of COLAZAL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COLAZAL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COLAZAL:-

You can seek FDA approval to launch a generic drug before the expiration of COMBIVENT RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMBIVENT RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMBIVENT RESPIMAT:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.